Download PDFPDF

JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Use of nicotinic acid in JBS2

    Dear Editor,

    With interest we read the new JSB guidelines but would like to clarify an issue relating to the correct licensed indication for nicotinic acid. Table 11 of the guidelines specifies that nicotinic acid be used in severe hypertriglyceridaemia with prior acute pancreatitis or not responsive to fibrates. The only formulation of nicotinic acid licensed for the treatment of dyslipidaemia is the prolonged re...

    Show More
    Conflict of Interest:
    None declared.